

Contents

List of Contributors XV

1	Some Facets of Molecular Disorder in Crystalline and Amorphous Pharmaceuticals 1
	<i>Marc Descamps and Jean-François Willart</i>
1.1	The Crystal/Amorph Alternative 2
1.1.1	Crystal/Amorph Alternative: Terminology and Solidity Concept 2
1.1.2	Crystal/Amorph Alternative: Structural Order and Disorder 3
1.1.2.1	Perfect Crystals 3
1.1.2.2	Crystal Size Effect 5
1.1.2.3	Imperfect Crystals: How Disordered Can a Crystal Be? 7
1.1.2.4	Structure of Amorphous – Liquid or Glassy – Materials 12
1.1.3	Crystal/Amorph Alternative: Metastability and Interconversion 15
1.1.3.1	Thermodynamic Measure of Physical Stability, Driving Force, Disorder 15
1.1.3.2	Stability of the Amorphous State, Kinetics of Crystallization 16
1.1.3.3	The Interfacial Free Enthalpy γ : Structure Dependence and Disorder Effect 20
1.1.3.4	Concluding Remarks 22
1.1.4	Crystal/Amorph Alternative in the Context of Solubility 22
1.2	Characteristics of the Disorder in Glass Formers 28
1.2.1	Glass Formation by Supercooling: Calorimetric Phenomenology 28
1.2.1.1	The Glass Transition is not a Phase Transition 30
1.2.1.2	The Glass Transition is a Kinetic Phenomenon 31
1.2.2	T_g as a Transition from an Ergodic to a Non-Ergodic Situation 32
1.2.3	The Entropy Below T_g : The Kauzmann Paradox 33
1.2.4	Dynamic Features of the Disorder in Glass Formers: The Three Nons. Fragile <i>versus</i> Strong Classification 35
1.2.4.1	Above T_g : The Dramatic Non-Arrhenius Temperature Dependence of Viscosity and Relaxation Times 36
1.2.4.2	Possible Connection Between Dynamics and Thermodynamics 39
1.2.4.3	Above T_g : Non-Exponential Relaxations and Dynamic Heterogeneity 40

1.2.4.4	Below T_g : Aging, Nonlinearity, Secondary Relaxations	41
1.2.5	Fragility and Polyamorphism in the Energy Landscape View Point	49
1.2.5.1	Fragility and Landscape Topology View Point	49
1.2.5.2	Polyamorphism and Landscape Topology	50
	Acknowledgments	51
	References	51
2	Influence of Disorder on Dissolution	57
	<i>Khushboo Kothari and Raj Suryanarayanan</i>	
2.1	Introduction	57
2.2	Approaches to Enhance Solubility	59
2.3	Measuring the Solubility Advantage of Amorphous Compounds	64
2.4	Solid Dispersions	66
2.5	Polymer Properties	67
2.6	Drug–Polymer Interactions	70
2.7	Polymer Concentration	71
2.8	Other Formulation Components	73
2.9	Formulation Variables	74
2.10	Reliable Measurement of Supersaturation	75
2.11	Conclusion	76
	References	77
3	Crystal Imperfections in Molecular Crystals: Physical and Chemical Consequences	85
	<i>William Jones and Mark D. Eddleston</i>	
3.1	Introduction	85
3.2	General Aspects of Defects in Crystals	87
3.3	Role of Imperfections in Reactivity and Stability – Chemistry in the Perfect and Imperfect Lattice	92
3.4	Role in Physical Processes	96
3.5	Concluding Remarks	99
	References	99
4	Observation and Characterization of Crystal Defects in Pharmaceutical Solids	103
	<i>Mark D. Eddleston and William Jones</i>	
4.1	Introduction	103
4.2	Techniques for Characterizing Defects within Crystals	104
4.2.1	Transmission Electron Microscopy	105
4.2.1.1	Introduction to Transmission Electron Microscopy	105
4.2.1.2	Application of Transmission Electron Microscopy to the Analysis of Pharmaceutical Samples	107
4.2.1.3	Characterization of Defects Using Transmission Electron Microscopy	110

- 4.2.1.4 Examples of the Study of Defects in Pharmaceutical Crystals Using Transmission Electron Microscopy 112
- 4.2.2 X-ray Diffraction Topography 115
 - 4.2.2.1 Introduction to X-ray Topography 115
 - 4.2.2.2 Characterization of Defects Using X-ray Topography 116
 - 4.2.2.3 Application of X-ray Topography to the Analysis of Pharmaceutical Samples 117
- 4.2.3 Other Significant Methods for Characterizing Defects within Crystals 118
- 4.3 Techniques for Characterizing Defects Emergent at Crystal Surfaces 119
 - 4.3.1 Atomic Force Microscopy 119
 - 4.3.1.1 Introduction to Atomic Force Microscopy 119
 - 4.3.1.2 Characterization of Defects Using Atomic Force Microscopy 121
 - 4.3.1.3 Examples of the Study of Defects in Pharmaceutical Crystals Using Atomic Force Microscopy 121
 - 4.3.2 Surface Etching 123
 - 4.3.2.1 Introduction to Chemical Etching 123
 - 4.3.2.2 Characterization of Defects Using Chemical Etching 123
 - 4.3.2.3 Examples of the Study of Defects Emergent at the Surfaces of Pharmaceutical Crystals Using Chemical Etching 124
 - 4.3.3 Other Relevant Methods for Characterizing Defects Emergent at Crystal Surfaces 125
- 4.4 Techniques for Quantifying Defect Densities within Crystals 125
- 4.5 The Complementarity of Techniques for Characterizing Defects 126
- 4.6 Summary and Outlook 127
- Acknowledgment 128
- References 128

- 5 **"Enantiomeric Disorder" Pharmaceutically Oriented** 135
Gerard Coquerel and Rui Tamura
 - 5.1 Introduction 135
 - 5.2 Introduction and Lexicon of Specific Terms Used among Chiral Molecules and Chiral Molecular Associations 135
 - 5.3 Restrictions in Symmetry Operations Inside Crystal Lattices with an Enantiomeric Excess Different from Zero 136
 - 5.4 Impact of Chirality on Phase Diagrams and the Gibbs–Scott Phase Rule 137
 - 5.4.1 Level 1: Amorphous Mixtures: Complete Spatial Disorder 138
 - 5.4.2 Level 2: In Crystallized Phases (Solid Solutions) 139
 - 5.4.2.1 Disorders Not Affecting the Stereogenic Centers (Nontreated) 140
 - 5.4.2.2 Disorders Affecting the Handedness of the Molecules (Examples) 140

5.5	Competitions between Solid Solutions (Impact of Polymorphism on Solid Solutions) Application: Preferential Enrichment	149
5.5.1	Discovery and Feature of Preferential Enrichment	149
5.5.2	Crystalline Nature of the Compounds Showing Preferential Enrichment	150
5.5.3	Mechanism and Requirements	152
5.5.4	Extension to Racemic Compound Crystals	152
5.6	Disorder at Level 3 Multiepitaxy between Enantiomers	154
5.7	Conclusion and Perspectives	156
	Acknowledgments	157
	References	157
6	Conformational Disorder and Atropisomerism in Pharmaceutical Compounds	161
	<i>Attilio Cesàro, Barbara Bellich, Giovanna Giannini, and Alessandro Maiocchi</i>	
6.1	Premise: Conformational Energy Barriers in Flexible Molecules	161
6.2	Conformational Topology and Crystallization of Chain Molecules	162
6.3	Conformational Polymorphism and Crystallization of Flexible Molecules	165
6.3.1	Conformational Polymorphism	165
6.3.2	Flexibility and Crystallization	167
6.3.3	Prediction of Conformational Polymorphs	169
6.4	Conformational Flexibility of Ring Molecules: Carbohydrates	170
6.5	Hindered Conformational Isomerism: Atropisomerism	172
6.5.1	Atropisomerism in Iodinated Contrast Media (ICM)	175
6.6	Conclusion	178
	Acknowledgments	180
	References	180
7	Tautomerism in Drug Delivery	183
	<i>Zaneta Wojnarowska and Marian Paluch</i>	
7.1	Broadband Dielectric Spectroscopy as a Powerful Tool for Investigating the Tautomerization Process in Condensed Materials	187
7.2	Tautomerization Kinetics of Supercooled Pharmaceuticals	190
	Acknowledgment	197
	References	198
8	Disorders in Pharmaceutical Polymers	201
	<i>Emeline Dudognon and Sheng Qi</i>	
8.1	Polymers Architectures – Structural Disorders	202
8.1.1	Architectures	202
8.1.2	Local Structure of Linear Polymers	202
8.1.2.1	Stereoregularity and Configurations	202

8.1.2.2	Conformations of Chains	203
8.2	Structural States and Phases Transitions	205
8.2.1	Amorphous Phase	205
8.2.2	Crystalline Structures	206
8.2.3	The Case of Copolymers: Organized Amorphous Structure	212
8.3	Dynamic Disorders	213
8.3.1	Glass–Rubber Transition Behavior	213
8.3.2	Mobilities	215
8.3.2.1	Localized Processes	215
8.3.2.2	Main Relaxation Process	217
8.3.2.3	Global Chain Dynamics	219
8.4	Blends of Polymer and Small Molecules	221
8.4.1	Glass Transition of the Blends	221
8.4.2	Mixing Free Energy of Blends of Polymers and Small Molecules	223
8.4.3	Solubility Limit of Small Molecules in Polymers	223
8.5	Effect of the Structural Properties of Pharmaceutical Polymers on Their Physical Behavior	224
8.5.1	Linear Polymers	225
8.5.1.1	Semicrystalline Polymers	225
8.5.1.2	Amorphous Polymers	230
8.5.2	Copolymers	232
8.6	Concluding Remarks	234
	References	235
9	Polymer Gels, Hydrogels, and Scaffolds – An Overview	241
	<i>Madeleine Djabourov and Kawthar Bouchemal</i>	
9.1	Introduction	241
9.2	Gels and Hydrogels	243
9.2.1	What Is a Gel?	244
9.2.2	Different Types of Gels	245
9.2.2.1	Chemical Gels	245
9.2.2.2	Physical Gels	245
9.2.2.3	Hydrogels	246
9.2.2.4	Hybrid Gels	248
9.2.3	General Properties of Polymer Networks	249
9.2.3.1	Background on Entropic Elasticity	250
9.2.3.2	Elasticity of Physical Gels	251
9.2.3.3	Network Swelling	256
9.2.3.4	Swelling and Biodegradation	259
9.2.4	The Sol–Gel Transition	261
9.2.5	Selected Examples of Gels	264
9.2.5.1	Gelatin Gels	264
9.2.5.2	Gelatin Hydrogels	265
9.2.5.3	Ploxamer Gels	266
9.3	Scaffolds	268

9.3.1	Thermally Induced Phase Separation (TIPS) with Solvent Crystallization: Cryogels	270
9.3.2	Spinodal Decomposition in Ternary Systems: Polymer/Solvent/Non-Solvent	271
9.3.3	Spinodal Decomposition in Organic–Inorganic Composite Scaffolds	273
9.3.4	Supercritical Processing	274
9.3.5	Other Scaffold Manufacturing Techniques	275
9.4	Conclusion	275
	References	276
10	Use of the Pair Distribution Function Analysis in the Context of Pharmaceutical Materials	283
	<i>Pierre Bordet and Pauline Martinetto</i>	
10.1	Introduction	283
10.2	What Is the PDF?	284
10.3	How to Measure the PDF	288
10.4	Modeling of the PDF	290
10.5	Applications of PDF Analysis to Molecular and Pharmaceutical Compounds	292
10.5.1	Polymorphs of <i>rac</i> -Modafinil	294
10.5.2	Effects of Grinding on Hydrochlorothiazide	296
10.6	Conclusion	297
	Acknowledgments	298
	References	298
11	Application of Broadband Dielectric Spectroscopy to Study Molecular Mobility in Pharmaceutical Systems	301
	<i>Katarzyna Grzybowska, Karolina Adrjanowicz, and Marian Paluch</i>	
11.1	Introduction to Broadband Dielectric Spectroscopy	301
11.1.1	Broadband Dielectric Spectroscopy Technique (10^{-5} to 10^{11} Hz)	301
11.1.2	Principles and Models of Dielectric Relaxation	303
11.1.2.1	Debye Relaxation	303
11.1.2.2	Non-Debye Relaxation Models	307
11.1.3	Identification of Relaxation Processes in Dielectric Spectra	312
11.1.3.1	Structural Relaxation α	312
11.1.3.2	Relaxation α' (Normal Mode)	314
11.1.3.3	Secondary Relaxations and Excess Wing	314
11.2	Molecular Dynamics in Amorphous Pharmaceutical Systems	316
11.2.1	Molecular Mobility in the Liquid and Glassy States of Drugs – Physical Factors that Can Govern Crystallization	316
11.2.1.1	Molecular Mobility in Supercooled Liquids (Structural α -Relaxation, Fragility)	317

- 11.2.1.2 Molecular Mobility in the Glassy State (Secondary Relaxation Processes) 322
- 11.2.2 Physical Stability of Drugs in the Liquid and Glassy States 324
- 11.2.2.1 Prediction of Physical Stability of Amorphous Drugs from Molecular Mobility Studies (At $T < T_g$) 324
- 11.2.2.2 Relation Between Cold Crystallization of Liquid and Molecular Mobility 327
- 11.2.2.3 Crystallization in the Glassy State 335
- 11.2.2.4 Enhancement of the Physical Stability of Amorphous Drugs by Preparing Amorphous Mixtures 339
- 11.3 Molecular Mobility and Dielectric Response in Partially Ordered Pharmaceutical Systems 346
- Acknowledgment 353
- References 353

- 12 Raman Spectroscopy in Disordered Molecular Compounds: Application to Pharmaceuticals 361**
Alain Hedoux
- 12.1 Introduction 361
- 12.2 Raman Spectroscopy 362
- 12.2.1 Basic Theory 362
- 12.2.2 Equipment and Procedures 364
- 12.2.3 Analysis of Raman Spectra of Molecular Compounds 365
- 12.2.3.1 Analysis of the Low-Frequency Raman Spectrum 366
- 12.2.3.2 Analysis of the High-Frequency Spectrum 369
- 12.3 Analysis of Molecular Compounds by Raman Spectroscopy 370
- 12.3.1 The Use of the LFRS to Distinguish Micro/Nanocrystals from the Amorphous State 370
- 12.3.1.1 Analysis of Polyamorphic Situations 370
- 12.3.1.2 Detection and Quantification of Crystallization in Ground Powder 371
- 12.3.2 The use of the LFRS to Reveal and Analyze Disordered States 374
- 12.3.2.1 Ibuprofen: Chirality and Disorder 374
- 12.3.2.2 Evidence of Different Structural Organizations in Amorphous Glucose Obtained by Thermal and Non-Thermal Routes 376
- 12.3.3 Use of LFRS for the Structural Description of Disordered Phases and the Analysis of Phase Transformations 378
- 12.3.3.1 Structural Description of Form II of Caffeine 378
- 12.3.3.2 Analysis of Polymorphic Transformations in Caffeine 381
- 12.3.4 The Use of Multivariate Analysis 382
- 12.3.4.1 Analysis of Spectra Collected in a Series of Samples 382
- 12.3.4.2 Raman Mapping 386
- 12.4 Conclusion 388
- References 388

13	Study of Disordered Materials by Terahertz Spectroscopy	393
	<i>Juraj Sibik and J. Axel Zeitler</i>	
13.1	Introduction	393
13.2	Exploration of Terahertz Dynamics Prior to THz-TDS	394
13.2.1	Poley Absorption	394
13.2.2	Far-Infrared Spectroscopy	395
13.2.3	Raman and Neutron Scattering	396
13.3	Response of Supercooled Liquids and Glasses at Terahertz Frequencies	397
13.3.1	Primary (α -) and Secondary (β -) Relaxations	397
13.3.2	Fast Secondary Relaxation and Caged Dynamics	398
13.3.3	Vibrational Density of States	399
13.4	Terahertz Studies of Disordered Molecular Solids	400
13.4.1	Disordered Crystals	400
13.4.2	Polymers	402
13.4.3	Inorganic Glasses	403
13.5	Organic Glass-Forming Liquids	404
13.5.1	Hydrogen-Bonded Liquids and Solutions	404
13.5.2	Supercooled Liquids and Glasses	407
13.6	Characterization of Disordered Biological and Pharmaceutical Systems	410
13.6.1	Quantifying Crystallinity	410
13.6.2	Crystallization of Amorphous Drugs Above T_g	410
13.6.3	Crystallization of Amorphous Drugs Below T_g	413
13.6.4	Stability of Amorphous Drugs Below T_g	414
13.6.5	Multicomponent Disordered Pharmaceutical Systems	416
13.7	Outlook	416
	References	418
14	Study of Disorder by Solid-State NMR Spectroscopy	427
	<i>Marco Geppi, Silvia Borsacchi, and Elisa Carignani</i>	
14.1	Introduction	427
14.2	Basics of Solid-State NMR	428
14.3	Static Disorder	433
14.3.1	Crystalline Systems	436
14.3.2	Amorphous Systems	441
14.3.2.1	Quantitation of Amorphous Phases	443
14.3.2.2	Miscibility and Interactions in Heterophasic Systems and Formulations	446
14.4	Dynamic Disorder	448
14.4.1	Interconformational Motions in Crystalline Systems	450
14.4.2	Global Motions in Amorphous Systems	454
14.5	A Case Study	458
14.6	Final Remarks and Future Perspectives	462
	References	464

15	Processing-Induced Disorder in Pharmaceutical Materials	467
	<i>Sheng Qi</i>	
15.1	Introduction	467
15.2	Pharmaceutical Processing	468
15.2.1	Milling	468
15.2.2	Thermal Processing Techniques	470
15.2.2.1	Simple Melt-Fusion Method	471
15.2.2.2	Spray-Chilling/Congeaing	472
15.2.2.3	Melt-Granulation	472
15.2.2.4	Thermal Sintering/Curing	473
15.2.2.5	Dry Powder Coating	474
15.2.2.6	Hot-Melt Extrusion (HME) and Injection Molding	474
15.2.2.7	Other Emerging Thermal Processing Techniques	477
15.2.3	Solvent-Evaporation-Based Processing Techniques	478
15.2.3.1	Spray-Drying	480
15.2.3.2	Freeze-Drying	481
15.2.3.3	Film Coating and Casting	482
15.2.3.4	Emerging Solvent-Evaporation-Based Processing Technologies	483
15.3	Conclusion	484
	References	485
16	Patenting of Inventions Relating to Solid Forms, with Special Considerations on Disordered Forms	491
	<i>Bertrand Gellie</i>	
16.1	Patentability of Disordered Crystals	493
16.1.1	Clarity Problems in Claims for Disordered Crystals	493
16.1.2	Sufficient Disclosure of Disordered Crystals	494
16.1.3	Novelty of Dislocated Crystals	495
16.1.4	Inventive Step of Dislocated Crystals	496
16.2	Patentability of Co-crystals	496
16.2.1	Clarity Problems in Claims for Co-crystals	497
16.2.2	Sufficient Disclosure of Co-crystals	498
16.2.3	Novelty of Co-crystals	498
16.2.4	Inventive Step of Co-crystals	499
16.3	Patentability of Amorphous Forms	500
16.3.1	Clarity Problems in Claims for Amorphous Forms	501
16.3.1.1	Pure Amorphous Forms	501
16.3.1.2	Mixtures of Amorphous (and/or Polymorphic) Forms	503
16.3.1.3	Mixtures Comprising Amorphous Forms and a Stabilizer	503
16.3.2	Sufficient Disclosure of Amorphous Forms	503
16.3.3	Novelty of Amorphous Forms	504
16.3.4	Inventive Step of Amorphous Forms per se	506
16.3.4.1	Other Inventions Involving Amorphous Forms	508
16.3.4.2	Glass Materials	508
16.4	Patenting (Disordered) Nanocrystals	509

16.4.1	Clarity Problems in Claims for (Disordered) Nanocrystals	509
16.4.2	Sufficient Disclosure of (Disordered) Nanocrystals	510
16.4.3	Novelty of (Disordered) Nanoparticles	510
16.4.4	Inventive Step of (Disordered) Nanoparticles	510
16.5	Conclusions	511

Index	513
--------------	------------